(87 ± 13 versus 69 ± 10, P < 0.001). Rate at rest decreased 26 ± 15% and submaximal exercise rate diminished 24 ± 12%. Thirteen (81%) of the 16 patients exhibited at least 15% slowing of rate at rest and during submaximal exercise. Eleven patients (69%) reported alleviation of symptoms. There was no change in serum digoxin levels during diltiazem treatment (1.3 ± 0.5 versus 1.3 ± 0.6 ng/ml, p = NS). On withdrawal of diltiazem, ventricular response returned to baseline values.
Diltiazem is an effective agent for control of ventricular response, both at rest and during exercise, in digoxin-treated patients with chronic atrial fibrillation.
(J Am Coil CardioI1987;9:40S-11)
node. In multiple studies, verapamil has been shown to terminate AV node reentrant tachycardia (15, 16) as well as decrease both the rest and exercise ventricular response in atrial fibrillation (1, [4] [5] [6] [7] 17) . Diltiazem has electrophysiologic properties similar to those of verapamil (II , 14, 18, 19) and has been documented to prevent the induction of AV node reentry (20) (21) (22) . It was our goal to determine the value of diltiazem to impede AV conduction in patients with chronic atrial fibrillation. Thus. control of ventricular response was assessed at rest .. during controlled exercise and during daily activities.
Methods
Study patients (Table 1) . Nineteen patients with chronic atrial fibrillation were enrolled in the study and 16 completed the entire study protocol. Eleven were men and five Were women. The mean age was 66 ± 12 years (range 38 to 79). The study entry criterion required a ventricular response rate greater than 100 beats/min at the completion of a limited standardized exercise test (3 minutes, 3 miles/h, 0°grade). Digoxin was continued if it had previously been part of the DILTIAZEM Phase patient's medical regimen. For those taking digoxin, the digoxin dose was adjusted to maintain a serum level in the therapeutic range (0.5 to 2.0 ng/ml) before entry into the formal study. Once this dosage was determined, digoxin was continued throughout the study without adjustment. All but three patients were on long-term digoxin therapy. All other antiarrhythmic medications including beta-adrenergic blockers, calcium channel blockers and class 1 antiarrhythmic agents were discontinued at least five half-lives before the start of the formal study.
Exclusion criteria were recent use of an investigational drug, unstable angina or acute myocardial infarction, WolffParkinson-White syndrome, clinically significant renal or hepatic failure, sick sinus syndrome without a functioning pacemaker, uncontrolled hypertension, systolic blood pressure less than 95 mm Hg, cardiac or other diseases that prevented upright exercise, or a history of untoward reaction to diltiazem. A history of congestive heart failure was not a contraindication to participation.
All patients gave informed consent before participation in the study. The study protocol was approved by the Human Investigation Committee at this institution.
Study design. The study was divided into three open label phases (Fig. I) . The initial phase served as a baseline period to allow recording of baseline variables after the digoxin dose had been adjusted. The second phase involved the administration of diltiazem (Cardizem) and observation of its effect on specific variables. In the final phase diltiazem was withdrawn to provide a comparison period and to account for the effects of training (23) . Phases occurred as 3 consecutive I week periods.
During the baseline pretreatment phase 1, a history and physical examination were performed followed by a 12lead electrocardiogram, submaximal exercise treadmill test (3 minutes, 3 miles/h, 0°grade) and 24 hour ambulatory monitoring (Cardiodata MK3 system with analysis at George Washington University). Heart rate at rest was measured with the patient supine. Ventricular response and blood pressure were monitored at I minute intervals during and for 3 minutes after exercise testing. Ventricular response was counted over at least 20 seconds at I minute intervals. The patient then entered phase 2 and was treated with diltiazem, 60 mg four times daily. After 7 days a repeat examination including a 3 minute submaximal exercise test and 24 hour monitoring was performed. If peak exercise ventricular response was still greater than 135 beats/min, the diltiazem dose was increased to 90 mg four times daily and repeat testing was performed after an additional week of study. At the completion of phase 2 on maximal dose diltiazem therapy (60 or 90 mg four times daily) all patients underwent a symptom-limited (maximal) exercise test using a Bruce or modified Bruce protocol. This followed the :3 minute exercise test by a 15 minute rest period.
Patients entered pha se 3 after testing on treatment with the optimal diltiazem dose. Diltiazem was discontinued for 7 days whereon a complete examination was performed, includingsubmaximal (3 minute) and maximal exercise tests and 24 hour ambulatory monitor.
Digoxin serum levels were determined immediately before exercise at each visit and diltiazem levels by high pressure liquid chromatography at visits during phase 2. All exercise tests were performed 2 to 5 hours after the diltiazem dose was administered when diltiazem levels would be expected to achieve their peak concentration (18) . Careful observation for and documentation of adverse effects were made.
Analysis of data. Results are presented as mean ± SO. Statistical analysis was performed using the Student' s t test for paired and unpaired data.
Results
Nineteen patients met the criteria for entry into the study. but the study was terminated prematurely in three of them:
Submoximol oxi 01
Exercise Exercise one withdrew voluntarily without explanation and two developed intolerable side effects within 3 days of diltiazem therapy. The remaining 16 patients constituted the diltiazem study group listed in Table I . Results during active treatment (phase 2) are reported for the optimal (maximal) diltiazem dose: 60 mg four times daily in II patients and 90 mg four times daily in 4 patients; I patient was studied at 30 mg four times daily because of adverse effects at a greater dose (see later). Control of ventricular response. Therapy with diltiazem resulted in significant reductions in various rest and exercise variables ( Table 2 , Fig. 2 ). Ventricular response was reduced at rest, at all levels of submaximal exercise and at conclusion of the maximal exercise evaluation. Rest ventricular rate dropped 26 ± 15% and 3 minute submaximal exercise ventricular rate diminished 24 ± 12%. Thir- heart rate-systolic pressure product at maximal levels of exertion decreased significantly during diltiazem therapy, primarily because of a blunted rate response.
Maintenance serum diltiazem levels. The mean serum diltiazem level at maximal dosage was 234 ± 187 ng/rnl. Diltiazem level correlated only with the percent change in heart rate at rest (r = 0.55, P < 0.05).
Diltiazem interaction with digoxin. The serum level of digoxin in the 13 patients receiving digoxin before the start of therapy was 1.3 ± 0.5 ng/m!. During diltiazem therapy, the level was 1.3 ± 0.6 ng/ml (p = NS).
Symptomatic response. Eleven (69%) of the 16 patients in the study group had subjective alleviation of symptoms of fatigue, palpitation and breathlessness during the diltiazem treatment period. Four patients showed no improvement and one patient had slight worsening of symptoms.
Adverse effects. Two patients developed severe dizziness necessitating diltiazem discontinuation before exercise evaluation on treatment. Two patients developed an erythematous rash; however, medication could be continued to study completion. One patient experienced mild dizziness shortly after diltiazem administration and one described nausea only if diltiazem was not taken with meals. One study subject had mild transient edema. Another patient developed nausea, headache and edema while receiving diltiazem, 60 mg four times daily, and symptoms completely resolved when the dose was reduced to 30 mg four times daily. Four of the eight patients were older than 70 years or receiving 360 mg of diltiazem daily.
The one patient with preexistent congestive heart failure and chronic ventricular ectopic rhythm manifested sustained (40 seconds) ventricular tachycardia at a rate of 130/min during the second minute of the submaximal exercise test while receiving diltiazem, 60/mg. The episode was asymptomatic, without observed hemodynamic changes and was teen (81%) of the 16 patients exhibited at least 15% slowing of rate at rest and at 3 minutes of exercise.
Results during 24 hour ambulatory electrocardiographic monitoring showed a similar significant reduction in average ventricular response (Fig. 3) . The mean 24 hour ventricular rate declined 20 ± 8% and 13 patients (81%) achieved at least a 15% rate reduction. Minimal and maximal rates during long-term recording also demonstrated a significant decline.
Statistical analysis revealed that diltiazem effect during phase 2 was similar to that of both the predrug baseline period (phase 1) and the postdrug withdrawal period (phase 3). Phase I and phase 3 results were comparable.
Comparison of "slow" and "fast" groups. The total group was subclassified into patients whose pretreatment rest ventricular rate was "fast" (90 beats/min; nine patients) and those whose rate was "slow" (~90 beats/min; seven patients). Those in the fast group had a 32 ± 17% reduction in rest ventricular response from 107 ± 14 to 70 ± 13 beats/min and those in the slow group had an 18 ± 6% reduction from 82 ± 8 to 68 ± 6 beats/min (Fig. 4) . Percent rate reduction was significantly greater in the fast group (p < 0.05). Final rates at rest during treatment were not significantly different between these subgroups.
Exercise capacity. When comparing diltiazem and postdiltiazem maximal treadmill tests, there was no significant improvement in peak exercise level (metabolic equivalents [METS]) during active drug therapy (7.3 ± 2.4 METS in phase 2 versus 7.0 ± 2.3 in phase 3). In six patients (38%) exercise capacity improved by at least I MET during diltiazem therapy. These patients with exercise improvement were either younger «70 years old) or had underlying mitral valve disease.
Effect on blood pressure. During diltiazem treatment, diastolic blood pressure at rest fell slightly ( Table 2 ). The self-terminating. Exerci se before diltiazem during treatment with digoxin alone had revealed no ventricular tachycardia; however , baseline 24 hour Holter monitoring demon strated frequent and complex ventricular ectopic activity . After discontinuation of diltiazem and institution of specific antiarrhythmic therapy, repeat exercise stud ies revealed no ventricular tachycardia. No change in ventricular ectopic activity during diltiazem was noted in the other 15 patients .
There were no episodes of symptomatic bradycardia or regularization of rhythm during the period of diltiazem therapy . Hypotension did not occur in any patient and there were no episodes of orthostatic hypoten sion .
Discussion
Limitation of digoxin therapy. Digoxin therapy for rate control in atrial fibrillation is well entrenched in the tradition of cardiovascular medicine. Whereas digoxin has modest succes s in reducing rest ventricular response in atrial fibrillation, it has failed to prevent excessive tachycardia during exertion (1-10). Our study clearl y confirms these observations. In the baseline phase, submaximal exercise quickly produ ced ventricular rates above 150beats/min despite therapeutic digoxin levels . Others (5, 8 ) have demonstrated that increa sing digoxin doses to achieve levels in the upper therapeutic range also fails to significantly blunt exercise tachycardia. The explanation for these findings resides in digoxin ' s mechanism of action in chronic atrial fibrillation. Rate control by digoxin is primarly effected by cholinergic potentiation . During stress or exerci se, parasympathetic activity is overwhelmed by sympathetic discharges, thus negating digoxin's minimal autonomic effects .
Effects of beta-adrenergic blockade. Given the sympathetic effects on AV node function, it is logical to assume that beta-adrenergic blockade would be useful and, indeed, rest and exercise rate control has been achieved with this cla ss of drugs (2, 8, 9) . Beta-blockers, however, are limited by their well known side effects and often result in reduced exercise capac ity despite rate slowing. In one study (2) of nadolol in atrial fibrillation , 65% of the patients had a significant decrement in exercise time on beta-blocker therap y. A small group of propranolol-treated patients showed either no improvement or worsening of exerc ise tolerance (10) .
Calcium channel blockade as alternative therapy. Depolarization of AV node tissue is a calcium-dependent process by way of the slow channel. Calcium channel blockade with verapamil depresses AV node action potential amplitude and lengthens nodal refractoriness ( 14, 24 ). The effect s of verapamil on the electrical properties of the AV node are independ ent of autonomic influence s (24, 25) and continue to modulate AV conduction during exercise (26) . Oral verapamil therapy for chronic atrial fibrillation augments rate control in digitalized patients (1,4,6,7) , and can be satisfactory as monotherapy without concomitant digoxin (5).
Mean ventricular rate by 24 hour electrocardiographic monitoring is slowed (7, 17) and exercise rates are significantly reduced (I ,4-7) .
While oral verapamil exhibits efficacy in atrial fibrillation , definite limitations to its widespread use exist (27) including its negative inotropic properties (28, 29) , elevation of serum digoxin levels (30) (31) (32) , delayed drug accumulation (33) and emergence of accelerated junctional rhythm (34, 35) .
Efficacy of diltiazem for rate control in atrial fibrillation. Diltiazem shares with verapamil a potent negative dromotropic effect without significant negative inotropic effects (36) (37) (38) (39) . Mitchell et al. (40) found that diltiazem prolonged the atrial-His interval by 12% in sinus rhythm and by 22% in constant paced rhythm. Nodal functional refractory period lengthened 6%, nodal effective refractory period 16% and Wenckebach cycle length 13% in the same study (40) . Others (11, 14, 18, 19) have found similar AV node conduction delay and prolongation of refractoriness. These electrophysiologic properties, similar to but less potent than those of verapamil , make diltiazem potentially useful in the treatment of supraventricular tachycardias. Intravenous diltiazem was effective in the short-term management of paroxysmal supraventricular tach ycardia (AV node reentry with and without retrograde conduction in an accessory pathway) (20, 21) . Oral diltiazem succe ssfully prevented induction of paroxysmal supraventricular tachycardia and during the follow-up period maintained prophylaxis in a group of patients with recurrent arrhythmia (22) .
Given this background . diltiazem would be expected to reduce ventricular respon se in patients with atrial fibrillation. Thiesen et al. (41) noted a significant reduction in mean ventricular rates after the short-term administration of oral diltiazem and during oral maintenance therapy. Recently, Roth et al. (42) found a significant improvement in rest and exercise rate control when diltiazem was added to digoxin in 12 patients with primarily rheumatic heart disease and atrial fibrillation. Diltiazem therapy alone, particularly at high dose s, produced adequate rate reduction as well. In 3 weeks of follow -up , the digoxin-diltiazem combination also achieved significant rate reduction . Our study confirm s and expands these preliminary findings with diltiazem . Diltiazem -treated patients had moderate slowing of rest ventricular response, and rates were sharply blunted at all stages of submaximal exercise and at the peak of maximal exercise. These results are con sistent with diltiazem ' s direct effect on AV condu ction.
Ambulatory electrocardiographic monitoring provides a less artificial method for documenting drug efficacy. Diltiazem was capable of maintaining a slower average rate in the 24 hour period. The limits (maximal and minimal) of ventricular rate similarly changed during therapy .
We could not document an overall improvement in maximal exercise time in our study group as a whole. This failure to improve exercise capacity may be due to the ad-vanced age of our patients, which would impose unrelated restraints on exercise. The majority of patients did report subjective symptomatic improvement during the diltiazem trial; however, these were unblinded observations. Some investigators have found that reductions in heart rate are proportional to basal rates (4, 8, 9) consistent with the frequency dependence of calcium channel blockade (25) in verapamil-treated patients or dependence of sympathetic tone in beta-blocker-treated patients. We also found that those patients with atrial fibrillation whose heart rate was less than 90 beats/min at rest had much less slowing than those with faster rates. Diltiazem, therefore, can be safely added to the treatment regimen to prevent excess exercise tachycardia even when rest ventricular response is slowed with digoxin alone.
Previous studies of the interaction of diltiazem and digoxin have produced conflicting results showing either no change (43, 44) or an increase in digoxin levels (45) (46) (47) (48) . The addition of diltiazem in our patients chronically treated with digoxin produced no change in serum digoxin level, thus confirming the safety of this combination therapy (40) .
Adverse effects. These were more common than reported in antianginal therapy trials (49) . Undoubtedly this is a consequence of the high doses of diltiazem used in the study and the older age of our patients. The role of diltiazem in the one patient with ventricular tachycardia remains unclear. All other described side effects were not serious and could be reversed either spontaneously or with dose reduction or discontinuation of diltiazem. We found no incidence of bradycardia or hypotension.
Limitations of study. This study was neither blinded nor placebo controlled. Nonetheless, we carefully compared the primary end point of ventricular response effects during diltiazem therapy with periods both before and after treatment and consistently documented excellent rate control on drug therapy. Conclusions regarding symptomatic improvement and exercise capacity are limited by the unblinded format of the study. Our study does not answer whether chronic therapy with diltiazem will show sustained efficacy. Comparative efficacy of diltiazem to either digoxin alone or verapamil was not assessed. Whether lower diltiazem dosage will demonstrate efficacy with fewer adverse effects is unknown. Though three patients in this study treated with diltiazem alone had excellent results, this sample is too small to allow recommendations to be made regarding diltiazem as monotherapy.
Conclusion. Diltiazem is an effective agent for heart rate control in patients with chronic atrial fibrillation treated with concomitant digoxin. Symptoms were improved and results were confirmed at rest, during various levels of exertion and during 24 hour ambulatory monitoring. Diltiazem therapy had no effect on digoxin levels and was not associated with serious adverse effects.
